191 related articles for article (PubMed ID: 8093668)
1. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy.
Grogan TM; Spier CM; Salmon SE; Matzner M; Rybski J; Weinstein RS; Scheper RJ; Dalton WS
Blood; 1993 Jan; 81(2):490-5. PubMed ID: 8093668
[TBL] [Abstract][Full Text] [Related]
2. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells.
Sonneveld P; Schoester M; de Leeuw K
J Clin Oncol; 1994 Aug; 12(8):1584-91. PubMed ID: 7518859
[TBL] [Abstract][Full Text] [Related]
3. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
4. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma.
Pilarski LM; Belch AR
Blood; 1994 Feb; 83(3):724-36. PubMed ID: 7507731
[TBL] [Abstract][Full Text] [Related]
5. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.
Salmon SE; Dalton WS; Grogan TM; Plezia P; Lehnert M; Roe DJ; Miller TP
Blood; 1991 Jul; 78(1):44-50. PubMed ID: 1676918
[TBL] [Abstract][Full Text] [Related]
6. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.
Cornelissen JJ; Sonneveld P; Schoester M; Raaijmakers HG; Nieuwenhuis HK; Dekker AW; Lokhorst HM
J Clin Oncol; 1994 Jan; 12(1):115-9. PubMed ID: 7903690
[TBL] [Abstract][Full Text] [Related]
7. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma.
Schwarzenbach H
Med Oncol; 2002; 19(2):87-104. PubMed ID: 12180485
[TBL] [Abstract][Full Text] [Related]
8. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON.
Sonneveld P; Durie BG; Lokhorst HM; Marie JP; Solbu G; Suciu S; Zittoun R; Löwenberg B; Nooter K
Lancet; 1992 Aug; 340(8814):255-9. PubMed ID: 1353189
[TBL] [Abstract][Full Text] [Related]
9. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Dalton WS; Grogan TM; Meltzer PS; Scheper RJ; Durie BG; Taylor CW; Miller TP; Salmon SE
J Clin Oncol; 1989 Apr; 7(4):415-24. PubMed ID: 2564428
[TBL] [Abstract][Full Text] [Related]
10. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining.
Salmon SE; Grogan TM; Miller T; Scheper R; Dalton WS
J Natl Cancer Inst; 1989 May; 81(9):696-701. PubMed ID: 2565403
[TBL] [Abstract][Full Text] [Related]
11. Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells.
Wyler B; Shao Y; Schneider E; Cianfriglia M; Scheper RJ; Frey BM; Gieseler F; Schmid L; Twentyman PR; Lehnert M
Br J Haematol; 1997 Apr; 97(1):65-75. PubMed ID: 9136943
[TBL] [Abstract][Full Text] [Related]
12. Expression of p170 protein in multiple myeloma: a clinical study.
Ucci G; Petrini M; Riccardi A; Invernizzi R; Carulli G; Luoni R; Giordano M; Danova M
Hematol Oncol; 1992; 10(3-4):213-20. PubMed ID: 1356905
[TBL] [Abstract][Full Text] [Related]
13. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
Lepelley P; Soenen V; Preudhomme C; Lai JL; Cosson A; Fenaux P
Leukemia; 1994 Jun; 8(6):998-1004. PubMed ID: 7516032
[TBL] [Abstract][Full Text] [Related]
14. Elimination of drug-resistant myeloma tumor cell lines by monoclonal anti-P-glycoprotein antibody and rabbit complement.
Kulkarni SS; Wang ZM; Spitzer G; Taha M; Hamada H; Tsuruo T; Dicke KA
Blood; 1989 Nov; 74(6):2244-51. PubMed ID: 2572283
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).
Sonneveld P; Suciu S; Weijermans P; Beksac M; Neuwirtova R; Solbu G; Lokhorst H; van der Lelie J; Dohner H; Gerhartz H; Segeren CM; Willemze R; Lowenberg B; ; ;
Br J Haematol; 2001 Dec; 115(4):895-902. PubMed ID: 11843823
[TBL] [Abstract][Full Text] [Related]
16. Detection of multidrug resistance gene expression in multiple myeloma.
Dalton WS
Leukemia; 1997 Jul; 11(7):1166-9. PubMed ID: 9205007
[TBL] [Abstract][Full Text] [Related]
17. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
18. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M
Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101
[TBL] [Abstract][Full Text] [Related]
20. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance.
Sparrow RL; Hall FJ; Siregar H; Van der Weyden MB
Leuk Res; 1993 Nov; 17(11):941-7. PubMed ID: 7901453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
